FDA approves GSK’s shingles vaccine Shingrix

FDA approved Shingrix herpes zoster vaccine (HZ/su, GSK1437173A) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent shingles in adults ages 50 and older.

The CDC's Advisory Committee on Immunization Practices (ACIP) recommended its use. GSK spokesperson Sean Clements told BioCentury that Shingrix will be launched at the end of November, with a majority of insured individuals covered by mid-2018. Payer coverage does not begin until CDC announces its recommendations in the Mortality and Morbidity Weekly Report (MMWR), Clements added...